Paper36110930
Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy.
Nota SPFT and 6 others. Front Oncol, 2022. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy. Papers, record 36110930. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36110930
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34707200 | GD2 CAR T cells against human glioblastoma. | NPJ Precis Oncol | 2021 | https://conductscience.org/library/papers/34707200 | PubMed |
| 2 | 35110735 | Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. | Nature | 2022 | https://conductscience.org/library/papers/35110735 | PubMed |
| 3 | 33494834 | CAR T cells in solid tumors: challenges and opportunities. | Stem Cell Res Ther | 2021 | https://conductscience.org/library/papers/33494834 | PubMed |
| 4 | 20852124 | CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. | J Natl Cancer Inst | 2010 | https://conductscience.org/library/papers/20852124 | PubMed |
| 5 | 20455858 | CSPG4 in cancer: multiple roles. | Curr Mol Med | 2010 | https://conductscience.org/library/papers/20455858 | PubMed |
| 6 | 16181333 | Mechanisms of MHC class I-restricted antigen processing and cross-presentation. | Immunol Rev | 2005 | https://conductscience.org/library/papers/16181333 | PubMed |
| 7 | 25197555 | Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. | J Immunother Cancer | 2014 | https://conductscience.org/library/papers/25197555 | PubMed |
| 8 | 19738072 | Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. | Cancer Res | 2009 | https://conductscience.org/library/papers/19738072 | PubMed |
| 9 | 33824268 | CAR-T cell therapy: current limitations and potential strategies. | Blood Cancer J | 2021 | https://conductscience.org/library/papers/33824268 | PubMed |
| 10 | 30135176 | Tumor Antigen Escape from CAR T-cell Therapy. | Cancer Discov | 2018 | https://conductscience.org/library/papers/30135176 | PubMed |
| 11 | 28420036 | Dedifferentiated chondrosarcoma: A survival analysis of 159 cases from the SEER database (2001-2011). | J Surg Oncol | 2017 | https://conductscience.org/library/papers/28420036 | PubMed |
| 12 | 22004131 | CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. | Pigment Cell Melanoma Res | 2011 | https://conductscience.org/library/papers/22004131 | PubMed |
| 13 | 22991614 | Histopathologic Differentiation between Enchondroma and Well-differentiated Chondrosarcoma: Evaluating the Efficacy of Diagnostic Histologic Structures. | J Dent Res Dent Clin Dent Prospects | 2011 | https://conductscience.org/library/papers/22991614 | PubMed |
| 14 | 10199270 | Chondrosarcoma of bone: an assessment of outcome. | J Bone Joint Surg Am | 1999 | https://conductscience.org/library/papers/10199270 | PubMed |
| 15 | 18469852 | The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. | Oncogene | 2008 | https://conductscience.org/library/papers/18469852 | PubMed |
| 16 | 8077056 | The chondroitin sulfate proteoglycan NG2 is a tumour-specific antigen on the chemically induced rat chondrosarcoma HSN. | Int J Cancer | 1994 | https://conductscience.org/library/papers/8077056 | PubMed |
| 17 | 16765318 | Intrinsic radiation resistance in human chondrosarcoma cells. | Biochem Biophys Res Commun | 2006 | https://conductscience.org/library/papers/16765318 | PubMed |
| 18 | 33912442 | High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease. | Front Oncol | 2021 | https://conductscience.org/library/papers/33912442 | PubMed |
| 19 | 11953591 | Treatment and outcome of recurrent pelvic chondrosarcoma. | Clin Orthop Relat Res | 2002 | https://conductscience.org/library/papers/11953591 | PubMed |
| 20 | 29567707 | CAR T cell immunotherapy for human cancer. | Science | 2018 | https://conductscience.org/library/papers/29567707 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42898659 | Application of CAR-T cell therapy in orthopedics: From bone malignancies to non-malignant musculoskeletal disorders. | J Orthop Translat | 2026 | https://conductscience.org/library/papers/42898659 | PubMed |
| 40969762 | Breaking barriers: enhancing CAR-armored T cell therapy for solid tumors through microenvironment remodeling. | Front Immunol | 2025 | https://conductscience.org/library/papers/40969762 | PubMed |
| 40867318 | Advances in the Molecular Biology of Chondrosarcoma for Drug Discovery and Precision Medicine. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40867318 | PubMed |
| 40004005 | Chondrosarcoma: New Molecular Insights, Challenges in Near-Patient Preclinical Modeling, and Therapeutic Approaches. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40004005 | PubMed |
| 39018437 | Chondroitin sulfate proteoglycan 4 increases invasion of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma by modifying transforming growth factor-β signalling. | Br J Dermatol | 2024 | https://conductscience.org/library/papers/39018437 | PubMed |
| 38891109 | Emerging Treatments Targeting the Tumor Microenvironment for Advanced Chondrosarcoma. | Cells | 2024 | https://conductscience.org/library/papers/38891109 | PubMed |
| 38735753 | Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy. | Proc Jpn Acad Ser B Phys Biol Sci | 2024 | https://conductscience.org/library/papers/38735753 | PubMed |
| 37745839 | Role of immunotherapy in chondrosarcoma: A case report and review of the literature. | Ther Adv Med Oncol | 2023 | https://conductscience.org/library/papers/37745839 | PubMed |
Genes12
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36110930
GET https://conductscience.org/api/papers/v1/36110930/references?page=2